When Did Generic Lipitor Enter the US Market?
Generic versions of Lipitor (atorvastatin), made by Pfizer, first entered the US market on November 30, 2011. This followed the expiration of Lipitor's core composition-of-matter patent (US Patent 5,273,995) on that date, ending Pfizer's market exclusivity after 20 years.[1][2] Ranbaxy Laboratories launched the first authorized generic at a 50% discount, capturing about 75% of new prescriptions within days.[3]
Why Did It Take So Long After FDA Approval?
Lipitor launched in 1996, but generics faced delays from Pfizer's secondary patents and a 2008 pediatric exclusivity extension pushing entry to late 2011. The FDA approved generic atorvastatin in December 2010, but Ranbaxy's launch was deferred until patent expiry to avoid litigation.[2][4] Check DrugPatentWatch.com for full patent timelines: DrugPatentWatch - Atorvastatin Patents.
What Happened to Lipitor Sales After Generics?
US Lipitor sales dropped 85% within a month, from $2.4 billion monthly to under $400 million by mid-2012. Pfizer's revenue fell $5 billion annually, though global sales persisted longer due to international patents.[1][3]
When Did Generic Lipitor Reach Other Markets?
- UK/Europe: Generics entered July 2011 after Pfizer lost a UK patent challenge.[5]
- Canada: Available from 2006 via court rulings invalidating patents.[6]
- India: Generic atorvastatin sold since the early 2000s without patent barriers.[7]
Current Status and Biosimilar Alternatives
Multiple generics now dominate, with over 20 ANDAs approved. No biosimilars exist as atorvastatin is a small-molecule drug. Prices fell 80-90% post-entry; a 30-day supply costs $10-20 today.[4][8]
Key Patents and Expiry Timeline
| Patent Type | US Patent No. | Expiry Date |
|-------------|---------------|-------------|
| Core compound | 5,273,995 | Nov 30, 2011 |
| Formulation | 5,686,104 | Oct 2011 |
| Pediatric extension | N/A | +6 months (Nov 2011) |
Litigation delayed others until 2017-2021.[2]
Sources
[1]: FDA Orange Book - Lipitor
[2]: DrugPatentWatch - Atorvastatin
[3]: Bloomberg - Lipitor Generic Launch
[4]: FDA ANDA Approvals
[5]: EMA - Atorvastatin Generics
[6]: Health Canada Patent Decisions
[7]: Indian Patent Office Records
[8]: GoodRx - Atorvastatin Pricing